Lalezari JP - Search Results

1

Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.

Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Yuen MF. Sulkowski MS, et al. Among authors: lalezari jp. J Hepatol. 2022 Nov;77(5):1265-1275. doi: 10.1016/j.jhep.2022.05.027. Epub 2022 Jun 11. J Hepatol. 2022. PMID: 35697332 Free article. Clinical Trial.

2

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.

Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS, Mulato AS, Lamy PD, Li W, Cherrington JM, Hellmann N, Kahn J. Deeks SG, et al. J Infect Dis. 1997 Dec;176(6):1517-23. doi: 10.1086/514150. J Infect Dis. 1997. PMID: 9395363 Clinical Trial.

3

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.

Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, Berrey M, Piscitelli S. Lalezari J, et al. AIDS. 2005 Sep 23;19(14):1443-8. doi: 10.1097/01.aids.0000183633.06580.8a. AIDS. 2005. PMID: 16135896 Clinical Trial.

4

Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.

Lalezari JP, Ward DJ, Tomkins SA, Garges HP. Lalezari JP, et al. J Antimicrob Chemother. 2007 Jul;60(1):170-4. doi: 10.1093/jac/dkm122. Epub 2007 May 8. J Antimicrob Chemother. 2007. PMID: 17491001 Clinical Trial.

5

Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.

Hanna GJ, Lalezari J, Hellinger JA, Wohl DA, Nettles R, Persson A, Krystal M, Lin P, Colonno R, Grasela DM. Hanna GJ, et al. Antimicrob Agents Chemother. 2011 Feb;55(2):722-8. doi: 10.1128/AAC.00759-10. Epub 2010 Nov 15. Antimicrob Agents Chemother. 2011. PMID: 21078951 Free PMC article. Clinical Trial.

6

Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects.

Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, Galindez J, Ernst JA, Martin DE, Palleja SM. Lalezari J, et al. J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25. doi: 10.1097/QAI.0b013e318213c2c0. J Acquir Immune Defic Syndr. 2011. PMID: 21317794 Clinical Trial.

7

The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.

Hopkins S, DiMassimo B, Rusnak P, Heuman D, Lalezari J, Sluder A, Scorneaux B, Mosier S, Kowalczyk P, Ribeill Y, Baugh J, Gallay P. Hopkins S, et al. J Hepatol. 2012 Jul;57(1):47-54. doi: 10.1016/j.jhep.2012.02.024. Epub 2012 Mar 13. J Hepatol. 2012. PMID: 22425702 Clinical Trial.

8

Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection.

Lalezari J, Asmuth D, Casiró A, Vargas H, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D. Lalezari J, et al. Antimicrob Agents Chemother. 2012 Dec;56(12):6372-8. doi: 10.1128/AAC.01521-12. Epub 2012 Oct 15. Antimicrob Agents Chemother. 2012. PMID: 23070151 Free PMC article. Clinical Trial.

9

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.

Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, Cornpropst MT, Mader M, Albanis E, Jiang D, Hebner CM, Symonds WT, Berrey MM, Lalezari J. Rodriguez-Torres M, et al. J Hepatol. 2013 Apr;58(4):663-8. doi: 10.1016/j.jhep.2012.11.018. Epub 2012 Nov 23. J Hepatol. 2013. PMID: 23183528 Clinical Trial.

10

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO. Sulkowski MS, et al. Hepatology. 2013 Jun;57(6):2143-54. doi: 10.1002/hep.26276. Hepatology. 2013. PMID: 23359516 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

119 results

Search Page